Paxlovid™ Prescribing Guidance – 6/21/2022

Paxlovid™ is now available at many retail pharmacies for prescription by any provider. We encourage providers to consider directly prescribing Paxlovid™ for their patients if they meet criteria, especially if they are close to 5 days of symptoms or if referral to the COVID High Risk Treatment pool would cause delay in treatment. If you are not sure if your patient is appropriate for Paxlovid, please continue to refer them to the COVID High Risk OP Treatment Referral-Adult pool using this power plan for assessment. It takes at least 24hrs for the pool to respond to a referral, and the pool is not staffed on weekends.

Power plan now available to assist prescribing:



This power plan should be used to **either prescribe Paxlovid™ OR refer a patient to the High Risk Outpatient Treatment** Pool to be assessed for Paxlovid™, bebtelovimab, or remdesivir.

Per the EUA, patients must meet the following criteria for treatment:

- 1. Positive COVID-19 test (self-reported home tests are acceptable)
- 2. Currently symptomatic
- 3. Within 5 days of symptom onset
- 4. ≥12 years old and ≥40kg
- 5. No hypoxia over baseline
- 6. Not hospitalized for COVID19 or expected to require imminent hospitalization
- 7. At least one risk factor for severe disease:
 - a. Age ≥ 65
 - b. Age <65 and at least one other risk factor see CDC list of risk factors for severe disease

<u>Prescribing Paxlovid™ using the AMB COVID High Risk OP Treatment Powerplan</u>

Date	Time	Physician Orders
		STEP 1
		Consider directly prescribing Paxlovid [™] for patients if they meet criteria or if referral to the COVID High Risk OP Treatment Referral-Adult pool would cause delay in treatment. It takes at least 24-72hrs for the pool to respond to a referral and the pool is not staffed on weekends.
		STEP 2
		Click on web link to review Inclusion Criteria / Outpatient Algorithm:
		Link: Adult/IUH-Outpatient-COVID-Treatment-Guidelines
		*Paxlovid™ is NOT recommended for patients with eGFR <30 mL/min or Child-Pugh class C hepatic impairment.
		*If patient does not meet criteria, order COVID High Risk OP Treatment Referral-Adult below.
		STEP 3
		<u>Prescribing Paxlovid™</u>
		 Determine if the patient has any significant drug-drug interactions using the <u>Liverpool COVID-19 Interactions</u> (covid19-druginteractions.org) reference. a. If your patient has a contraindicated drug interaction, please refer them to the COVID High Risk OP
		 Treatment Referral-Adult pool to be assessed for alternate therapies. (See order below) b. If your patient has a manageable drug-drug interaction, the prescribing provider must counsel the patient on managing the interaction. 2. May use the COVID 19 Public Therapeutic Locator to find a pharmacy to fill the prescription. 3. Provide Patients receiving Paxlovid™ the FDA Factsheet for Patients, Parents, and Caregivers
		STEP 4
		Medications
		eGFR equal to or greater than 60 mL/min:
		Rx: 300mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet), with all three
		tablets taken together twice daily for 5 days
		eGFR equal to or greater than 30 mL/min to less than 60 mL/min:
		Rx: 150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet), with both
		tablets taken together twice daily for 5 days
		Referral Order
		If you are not sure if your patient is appropriate for Paxlovid, please continue to refer them to the COVID High Risk OP Treatment *Referral-Adult* pool for assessment. It takes at least 24-72hrs for the pool to respond to a referral and the pool is not staffed on weekends.
		COVID High Risk OP Treatment Referral - Adult